Agios Pharmaceuticals, Inc. (LON:0HB0)

Market Cap	1.84B
Revenue (ttm)	29.83M
Net Income (ttm)	474.50M
Shares Out	n/a
EPS (ttm)	8.12
PE Ratio	3.87
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	242
Average Volume	258
Open	43.77
Previous Close	42.24
Day's Range	42.11 - 43.78
52-Week Range	23.82 - 62.60
Beta	n/a
RSI	58.13
Earnings Date	Oct 30, 2025

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patien...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2007
• Employees: 488
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HB0

Financial Performance

Financial numbers in USD